Role of biological therapy for inflammatory bowel disease in developing countries

Gut

Volumn 61, Issue 5, 2012, Pages 706-712

  Rogler, Gerhard ^a   Bernstein, Charles N ^b   Sood, Ajit ^c   Goh, Khean Lee ^d   Yamamoto Furusho, Jesús K ^e   Abbas, Zaigham ^f   Fried, Michael ^a,g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF MANITOBA   (Canada)

^c DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^f SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

^g World Gastroenterology Organisation   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO; PURINE DERIVATIVE; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; ENTERITIS; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MEDICAL ETHICS; PATIENT SELECTION; POSTPRIMARY TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; RESOURCE ALLOCATION; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VIRUS REACTIVATION; WORLD HEALTH ORGANIZATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; DEVELOPING COUNTRIES; DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC;

EID: 84859611482     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300613     Document Type: Review

References (84)

1. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 2008;57:1185-91.
2. Goh K, Xiao SD. Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis 2009;10:1-6.
3. http://www.reuters.com/article/idUSLH87077520090617.
4. Wang YF, Zhang H, Ouyang Q. Clinical manifestations of inflammatory bowel disease: East and West differences. J Dig Dis 2007;8:121-7. (Pubitemid 47161783)
5. El Mouzan MI, Abdullah AM, Al Habbal MT. Epidemiology of juvenile-onset inflammatory bowel disease in central Saudi Arabia. J Trop Pediatr 2006;52:69-71. (Pubitemid 43174784)
6. Sood A, Midha V, Sood N, et al. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol 2006;12:7332-6. (Pubitemid 44911842)
7. Sood A, Midha V, Sood N, et al. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003;52:1587-90. (Pubitemid 37363442)
8. Ouyang Q, Tandon R, Goh KL, et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006;21:1772-82. (Pubitemid 44656996)
9. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
10. Sood A, Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol 2007;26:285-9. (Pubitemid 351629632)
11. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112-24.
12. Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007;42:602-10. (Pubitemid 46633816)
13. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005;(1): CD003715.
14. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60. (Pubitemid 32729372)
15. Bebb JR, Scott BB. How effective are the usual treatments for Crohn's disease? Aliment Pharmacol Ther 2004;20:151-9. (Pubitemid 38998212)
16. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69. (Pubitemid 9242048)
17. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66. (Pubitemid 14218578)
18. Katz S. 'Mind the Gap': an unmet need for new therapy in IBD. J Clin Gastroenterol 2007;41:799-809. (Pubitemid 47442704)
19. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
20. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2:944-7.
21. Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974;66:916-22.
22. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7. (Pubitemid 10125406)
23. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72. (Pubitemid 23213520)
24. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine or combination therapy for Chrohn's disease. N Engl J Med 2010;362:1383-95.
25. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
26. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9. (Pubitemid 29468216)
27. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33. quiz 591.
28. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50. (Pubitemid 47080388)
29. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38. (Pubitemid 47080387)
30. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
31. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000543.
32. Hanauer SB. High-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 2006;24(Suppl 3):37-40. (Pubitemid 44326418)
33. Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 2005;39:557-69. (Pubitemid 41061259)
34. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9. (Pubitemid 18010466)
35. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-8.
36. Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960;1:217-22.
37. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(1):CD000478.
38. Ginsburg PM, Dassopoulos T. Steroid dependent ulcerative colitis: azathioprine use is finally 'evidence-based'. Inflamm Bowel Dis 2006;12:921-2. (Pubitemid 44352720)
39. Ghosh S, Chaudhary R, Carpani M, et al. Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease? Gut 2006;55:6-8. (Pubitemid 41820625)
40. Cohen RD. Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: long-awaited results? Gastroenterology 2006;130:607-8. (Pubitemid 43202062)
41. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5. (Pubitemid 24188135)
42. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
43. http://www.who.int/choice/costs/CER-levels/en/index.html.
44. Day H, Kinosian B. A tale of two walls. J Gen Intern Med 1998;13:718-19. (Pubitemid 28473802)
45. Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008;28:1230-9.
46. Williams JG, Cheung WY, Russell IT, et al. Open access follow up for inflammatory bowel disease: pragmatic randomised trial and cost effectiveness study. BMJ 2000;320:544-8. (Pubitemid 30175799)
47. Nugent Z, Blanchard JF, Bernstein CN. A population based study of health care resource use among infliximab users. Am J Gastroenterol 2010;105:2009-16.
48. Yamamoto-Furusho J, Rodríguez-Bores L, González-Contreras Q, et al. Prevalence and clinical features of indeterminate colitis in Mexico: A 17-year study. Rev Gastroenterol Mex 2010;75:30-5.
49. Yamamoto-Furusho JK. Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987-2006). J Clin Gastroenterol 2009;43:221-4.
50. Yamamoto-Furusho JK, Uscanga LF, Vargas-Alarcón G, et al. Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. Hum Immunol 2003;64:119-23. (Pubitemid 36109820)
51. Baumgart DC, Bernstein CN, Abbas Z, et al. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010-Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis 2011;17:639-44.
52. Qureshi H, Zuberi SJ, Banatwala N, et al. Ulcerative colitis in Karachi. J Gastroenterol Hepatol 1989;4:313-16. (Pubitemid 19204656)
53. Pache I, Rogler G, Felley C. TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Med Wkly 2009;139:278-87.
54. Hung HF, Chen TH. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Vaccine 2009;27:6770-6.
55. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in Chinaedeclining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27:6550-7.
56. Narahari S, Juwle A, Basak S, et al. Prevalence and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort. Infect Genet Evol 2009;9:643-5.
57. Song EY, Yun YM, Park MH, et al. Prevalence of occult hepatitis B virus infection in a general adult population in Korea. Intervirology 2009;52:57-62.
58. Todd CS, Ahmadzai M, Atiqzai F, et al. Prevalence and correlates of HIV, syphilis, and hepatitis knowledge among intrapartum patients and health care providers in Kabul, Afghanistan. AIDS care 2009;21:109-17.
59. Vitoria M, Granich R, Gilks CF, et al. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol 2009;131:844-8.
60. Mehtar S. Lowbury Lecture 2007: infection prevention and control strategies for tuberculosis in developing countries - lessons learnt from Africa. J Hosp Infect 2008;69:321-7.
61. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008;27:907-13.
62. Dinser R, Fousse M, Sester U, et al. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay. Rheumatology (Oxford) 2008;47:212-18. (Pubitemid 351168235)
63. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620-2.
64. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:2799-806.
65. Pai M. Alternatives to the tuberculin skin test: interferon-gamma assays in the diagnosis of mycobacterium tuberculosis infection. Indian J Med Microbiol 2005;23:151-8. (Pubitemid 41188486)
66. Pai M, Gokhale K, Joshi R, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 2005;293:2746-55. (Pubitemid 40973379)
67. Bhat J, Rao VG, Gopi PG, et al. Prevalence of pulmonary tuberculosis amongst the tribal population of Madhya Pradesh, central India. Int J Epidemiol 2009;38:1026-32.
68. Spira T, Lindegren ML, Ferris R, et al. The WHO/PEPFAR collaboration to prepare an operations manual for HIV prevention, care, and treatment at primary health centers in high-prevalence, resource-constrained settings: defining laboratory services. Am J Clin Pathol 2009;131:887-94.
69. Iliyasu Z, Babashani M. Prevalence and predictors of tuberculosis coinfection among HIV-seropositive patients attending the Aminu Kano Teaching Hospital, northern Nigeria. J Epidemiol 2009;19:81-7.
70. Hanifa Y, Grant AD, Lewis J, et al. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis 2009;13:39-46.
71. Lichauco JJ, Tankeh-Torres SA, Navarra SV, et al. Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents. APLAR J Rheumatol 2006:184-92. (Pubitemid 44057338)
72. Handa R, Misra R, Chaturvediv P, et al. Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-a treatment: Indian Rheumatology Association. APLAR J Rheumatol 2006:181-3. (Pubitemid 44057337)
73. Kumar A. Experience with anti-tumor necrosis factor-a therapy in India. APLAR J Rheumatol 2006;9:136-41. (Pubitemid 44057328)
74. Hur JW, Choi CB, Bae SC. Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients. APLAR J Rheumatol 2006;9:146-9.
75. Navarra SV, Raso AA, Lichauco JJ, et al. Clinical experience with infliximab among Filipino patients with rheumatic diseases. APLAR J Rheumatol 2006;9:150-6. (Pubitemid 44057331)
76. Thong BY, Vasoo S, Koh ET. The use of anti-tumour necrosis factora therapies for rheumatoid arthritis in Singapore. APLAR J Rheumatol 2006;9:157-60. (Pubitemid 44057332)
77. Huang F, Wang L, Zhang J, et al. Risk of tuberculosis in a Chinese registry of rheumatoid arthritis and ankylosing spondylitis for tumour necrosis factora antagonists. APLAR J Rheumatol 2006;9:170-4. (Pubitemid 44057335)
78. Keijzer A, van der Valk P, Ossenkoppele GJ, et al. Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha. Haematologica 2006;91(12 Suppl):ECR51.
79. Slusher JR, Maldonado ME, Mousavi F, et al. Central nervous system Aspergillus fumigatus presenting as cranial nerve palsy in a patient with ankylosing spondylitis on anti-TNF therapy. Rheumatology 2008;47:739-40. (Pubitemid 351619229)
80. Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clinic Proc 2008;83:181-94. (Pubitemid 351303102)
81. Bhattacharya M, Neogi SB. Estimation of mortality due to AIDS - a review. Indian J Public Health 2008;52:21-7.
82. Kallings LO. The first postmodern pandemic: 25 years of HIV/IDS. J Internal Med 2008;263:218-43. (Pubitemid 351207350)
83. Yamamoto-Furusho JK, Bosques-Padilla F. Mexican consensus on the use of agents anti-TNF-alpha in the treatment of inflammatory bowel disease (In Spanish). Rev Gastroenterol Mex 2009;74:263-78.
84. Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol 2008;22:621-41.